Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals to $62 from $53 and keeps an Outperform rating on the shares after the company reported interim data from their second iBAT asset, volixibat, in patients with primary biliary cholangitis, or PBC, and primary sclerosing cholangitis, or PSC. The “upside surprise in pruritis in the PBC trial spills over positively to PSC,” contends the firm, which thinks Mirum “looks poised to have the first approved drug in PSC.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals presents long-term data from LIVMARLI studies
- Citi opens ‘positive catalyst watch’ on Mirum into data
- Mirum Pharmaceuticals price target raised to $45 from $40 at Cantor Fitzgerald
- Atai Life Sciences appoints Braunstein, Fischer to supervisory board
- Mirum Pharmaceuticals participates in a conference call with Cantor Fitzgerald
Questions or Comments about the article? Write to editor@tipranks.com